| Abstrakt: |
A recent study conducted at Maggiore della Carita Hospital in Novara, Italy, examined the effectiveness and safety of direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) infection who also had glucose-6-phosphate dehydrogenase deficiency (G6PDd). The study, which included 2754 HCV-positive patients, found that the treatment of HCV with DAAs in patients with G6PDd was highly effective and safe, with no significant differences in hematochemical parameters and no treatment-related adverse events reported. This research provides valuable insights into the treatment of HCV in patients with G6PDd, a common comorbidity in countries like Italy. [Extracted from the article] |
